一种基于铁蛋白的 COVID-19 纳米颗粒疫苗，在非人类灵长类动物中引发了强大、持久、广谱的中和抗体血清。

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.

机构信息

Sarafan ChEM-H, Stanford University, Stanford, CA, USA.

Department of Chemistry, Stanford University, Stanford, CA, USA.

出版信息

Nat Commun. 2023 Apr 17;14(1):2149. doi: 10.1038/s41467-023-37417-9.

While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ~one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly (or less frequent) booster vaccine, and as a primary vaccine for pediatric use including in infants.

虽然 COVID-19 疫苗的快速发展是一项科学上的胜利，但仍需要一种全球可获得的疫苗，以提供针对当前和未来 SARS-CoV-2 关注变体（VOCs）的更持久免疫力。在这里，我们描述了 DCFHP，一种基于铁蛋白的蛋白质纳米颗粒疫苗候选物，当与作为唯一佐剂的氢氧化铝（DCFHP-alum）联合使用时，在非人类灵长类动物中引发针对已知 VOCs 的强大且持久的中和抗体，包括奥密克戎 BQ.1 以及 SARS-CoV-1。在初始免疫后约一年进行加强针接种后，DCFHP-alum 引发了强烈的回忆反应。为了实现全球可及性，我们生成了一种能够使每升细胞培养物生产数千剂疫苗的细胞系，并表明 DCFHP-alum 在标准室温以上至少 14 天内保持效力。DCFHP-alum 具有作为每年一次（或更频繁）加强针疫苗的潜力，也可作为儿科使用的主要疫苗，包括婴儿。